Edwards Lifesciences
Irvine, CA 92614
EDWARDS INTUITY Valve System Receives CE Mark
IRVINE, CA - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has received CE Mark in Europe for its EDWARDS INTUITY Valve System for use in patients undergoing surgical aortic valve replacement (AVR). The system, which consists of a bovine pericardial heart valve and novel delivery system,...
Read More »Edwards SAPIEN 3 TAVI Receives Expanded Approval in Europe
Superior TAVI Valve Indicated for All Patients Diagnosed with Aortic Stenosis Irvine, Calif., Nov. 6, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the...
Read More »Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients
SAN FRANCISCO, Sept. 29, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced new data demonstrating early and sustained health status advantages for severe aortic stenosis (AS) patients at low surgical risk treated with the Edwards SAPIEN 3 valve. Study...
Read More »Edwards Comments on Updated TAVR National Coverage Determination
IRVINE, Calif., June 21, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today commented on the final updated U.S. Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) pertaining to transcatheter aortic valve replacement (TAVR) programs:...
Read More »Edwards Lifesciences Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Corporation
IRVINE, Calif., June 3, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation to purchase up to 1,000,000 shares, or approximately 0.48 percent of the company's...
Read More »Edwards Lifesciences Announces Strategic Investments
IRVINE, Calif., March 11, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart disease technologies. Edwards has invested $35 million in an exclusive right to acquire Corvia Medical, Inc., the...
Read More »Edwards Lifesciences Enters Into Agreement to Acquire CASMED
Irvine, Calif. and Branford, Conn., Feb. 12, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has entered into a definitive merger agreement to acquire CAS Medical Systems, Inc. (NASDAQ: CASM) (CASMED), a medical technology company dedicated to...
Read More »Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives CE Mark
IRVINE, Calif., Nov. 16, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it has received CE Mark for the SAPIEN 3 Ultra system for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients. The SAPIEN 3 Ultra system...
Read More »Edwards Comments on German Court Decision
IRVINE, Calif., Oct. 23, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that today the district court in Düsseldorf, Germany, granted Boston Scientific's request for a preliminary injunction on future commercial sales and, therefore, patient treatments using...
Read More »Edwards Announces Start of U.S. Study of Self-Expanding Transcatheter Heart Valve
IRVINE, Calif., Oct. 8, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has commenced the U.S. pivotal trial that will study its self-expanding CENTERA transcatheter valve for severe, symptomatic aortic stenosis (AS) patients at intermediate risk of...
Read More »Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal to Impact One Million Underserved People Ahead of Schedule
Cumulative work of 60 non-profit partners now expected to reach 1.5 million by 2020 IRVINE, Calif., Sept. 26, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced at a 60th anniversary educational event that the Every Heartbeat Matters initiative has exceeded the goal...
Read More »